4DMedical Raises $22.6M, Boosting Cash to $45.5M Ahead of Key US Expansion
4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.
- Raised $22.6 million via exercise of 4DXOA options at $0.55 each
- Pro forma cash balance now $45.5 million as of June 30, 2025
- Additional $30.2 million potential from in-the-money options expiring December 2025
- Funds earmarked for US market expansion and CT – VQ™ commercialisation
- Ongoing R&D and post-FDA clearance studies to broaden clinical applications
Capital Injection Strengthens 4DMedical’s Position
4DMedical Limited (ASX – 4DX), a pioneer in respiratory imaging technology, has successfully raised $22.6 million through the exercise of deep in-the-money options, with an overwhelming 99.7% of the 4DXOA options converted. This capital boost lifts the company’s pro forma cash balance to $45.5 million as of June 30, 2025, providing a solid financial foundation for its next phase of growth.
Strategic Focus on US Market and CT – VQ™ Rollout
The fresh funds come at a critical time as 4DMedical accelerates the commercialisation of its flagship CT – VQ™ technology, which combines ventilation and perfusion analysis to set new standards in cardiothoracic imaging. The company aims to deepen penetration into the US healthcare market, leveraging a reseller agreement with Philips to access academic medical centres, health systems, and radiology networks.
CEO Andreas Fouras highlighted the importance of this capital in executing commercial plans and preparing for the upcoming RSNA 2025 conference, a key event for showcasing innovations in respiratory imaging.
Further Capital Opportunities on the Horizon
Beyond the recent option exercise, 4DMedical has an additional 22.1 million options (ASX – 4DXO) currently in-the-money, with an exercise price of $1.365 and expiry at the end of 2025. If exercised, these could inject up to $30.2 million more into the company’s balance sheet, further extending its financial runway.
Innovation and Research Drive Long-Term Growth
Alongside commercial expansion, 4DMedical continues to invest in research and development, including post-FDA clearance studies for CT – VQ™ and broadening its portfolio of clinical applications. The company’s acquisition of AI specialist Imbio in 2023 has enhanced its capabilities, positioning it at the forefront of medical imaging innovation.
This blend of strong capital backing, strategic partnerships, and ongoing innovation underscores 4DMedical’s ambition to redefine respiratory care globally.
Bottom Line?
With a strengthened balance sheet and promising market opportunities, 4DMedical is poised for a pivotal year ahead.
Questions in the middle?
- Will the remaining $30.2 million in options be exercised before year-end?
- How quickly will CT, VQ™ adoption accelerate in the competitive US healthcare market?
- What new clinical applications might emerge from ongoing R&D efforts post-FDA clearance?
